Small Molecule Outsourcing: Getting Timelines, Tech Transfer, And Analytics Right

Outsourcing small molecule drug development and manufacturing remains complex—but staying on track with timelines is still critical. Success depends on seamless technology transfers and robust analytical strategies.

In this session, industry experts share best practices for streamlining processes between sponsors and CDMOs. You'll walk away with actionable insights into aligning analytical methods and quality standards to accelerate small molecule production and reduce risk across the development lifecycle.

Hosted by Jeff Buguliskis, Ph.D., Deputy Chief Editor, Outsourced Pharma

With Panelists:

• Vadim Klyushnichenko, Ph.D., VP Bio/Pharmaceutical Development & Quality, Calibr-Skaggs Institute for Innovative Medicines
• April Loui, SVP Quality and CMC Regulatory, ReCode Therapeutics,Founder, CEO at Clarity Global Pharma
• Natalie Farris, Executive CMC Consultant, Naltou Pharma CMC Consulting, LLC
• Thierry Bilbault, Co-founder and Principal, JT Biopharma Partners, Fmr. SVP Tech Ops Ardelyx